Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 9,500 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the sale, the vice president now owns 47,206 shares in the company, valued at approximately $3,295,450.86. The trade was a 16.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $69.86 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market cap of $41.07 billion, a price-to-earnings ratio of 10.02, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The firm’s 50-day moving average is $71.28 and its 200 day moving average is $70.76.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently bought and sold shares of the business. Prosperity Consulting Group LLC grew its position in Edwards Lifesciences by 3.6% in the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock worth $289,000 after purchasing an additional 134 shares during the period. Abacus Planning Group Inc. increased its position in Edwards Lifesciences by 0.3% during the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after acquiring an additional 140 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock valued at $123,000 after acquiring an additional 145 shares during the period. Bowman & Co S.C. boosted its position in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after purchasing an additional 148 shares during the last quarter. Finally, Kera Capital Partners Inc. grew its stake in shares of Edwards Lifesciences by 5.0% during the 1st quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 148 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EW. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Evercore ISI reduced their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $78.55.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.